Science and Mechanism of Action of Targeted Therapies in Cancer Treatment
Author:
- Debra WujcikDWDebra Wujcik
- 1 August 2014
- journal article
- review article
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 30 (3) , 139-146
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Precision Medicine for Nurses: 101Seminars in Oncology Nursing, 2014
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung AdenocarcinomaJournal of Thoracic Oncology, 2013
- Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyJournal of Cancer, 2013
- Translating genomic information into clinical medicine: Lung cancer as a paradigmGenome Research, 2012
- Molecular Biology of Lung Cancer: Clinical ImplicationsClinics in Chest Medicine, 2011
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient SelectionJournal of Clinical Oncology, 2009
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001